Printed from Voxsanity (voxsanity.com.au) — NCT05552222 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
AI generated eligibility summary.
Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source.
How we use AI
Who might be able to join this trial:
People who have been diagnosed with multiple myeloma according to standard international diagnostic guidelines
People who have been newly diagnosed and are not suitable for high-dose chemotherapy with a stem cell transplant — either because of older age, because other health conditions make that treatment too risky, or because the transplant is being delayed as a first treatment option
People whose general physical functioning is rated at a certain level (scored 0 to 2 on a standard scale used by doctors to measure how well a person can carry out daily activities)
People who agree not to be pregnant, breastfeeding, or planning to become pregnant during the study or within 6 months after their last dose of study treatment
People who agree not to plan to father a child during the study or within 100 days after their last dose of study treatment
Who may not be able to join:
People who have already received treatment for multiple myeloma or an earlier stage of the condition called smoldering myeloma, except for a small, short course of steroid medication (within specific dose limits set by the trial)
People who have had a blood-filtering procedure called plasmapheresis within 28 days before joining the trial
People who have had a stroke, a brief stroke-like episode (sometimes called a mini-stroke), or a seizure within the 6 months before joining the trial
People with known allergies or sensitivities to certain study drugs (teclistamab or talquetamab) or their ingredients
People for whom certain other study medications (daratumumab or lenalidomide) are not recommended according to standard prescribing guidelines
People who score 2 or higher on a specific frailty measurement scale used for myeloma patients, unless that score is based only on age (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
Contact this trial
Principal Investigator: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Barwon Health - University Hospital Geelong, Geelong,
Liverpool Hospital, Liverpool,
Sir Charles Gairdner Hospital, Nedlands,
Calvary Mater Newcastle Hospital, New South Wales,
Wollongong Hospital, Wollongong,
Princess Alexandra Hospital, Woolloongabba,
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Voxsanity
Clinical trials and treatments, explained plainly · voxsanity.com.au
Date:
To: My Doctor
Re: Clinical trial enquiry
I am writing to enquire about the following clinical trial which may be relevant to my care:
Trial: NCT05552222
Sponsor: Janssen Research & Development, LLC
Phase: Phase 3
Status: Recruiting
Condition: Myeloma
Trial contact: 844-434-4210
More information: https://clinicaltrials.gov/study/NCT05552222
Eligibility summary (AI generated)
Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.
Who might be able to join this trial:
People who have been diagnosed with multiple myeloma according to standard international diagnostic guidelines
People who have been newly diagnosed and are not suitable for high-dose chemotherapy with a stem cell transplant — either because of older age, because other health conditions make that treatment too risky, or because the transplant is being delayed as a first treatment option
People whose general physical functioning is rated at a certain level (scored 0 to 2 on a standard scale used by doctors to measure how well a person can carry out daily activities)
People who agree not to be pregnant, breastfeeding, or planning to become pregnant during the study or within 6 months after their last dose of study treatment
People who agree not to plan to father a child during the study or within 100 days after their last dose of study treatment
Who may not be able to join:
People who have already received treatment for multiple myeloma or an earlier stage of the condition called smoldering myeloma, except for a small, short course of steroid medication (within specific dose limits set by the trial)
People who have had a blood-filtering procedure called plasmapheresis within 28 days before joining the trial
People who have had a stroke, a brief stroke-like episode (sometimes called a mini-stroke), or a seizure within the 6 months before joining the trial
People with known allergies or sensitivities to certain study drugs (teclistamab or talquetamab) or their ingredients
People for whom certain other study medications (daratumumab or lenalidomide) are not recommended according to standard prescribing guidelines
People who score 2 or higher on a specific frailty measurement scale used for myeloma patients, unless that score is based only on age (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.
This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.
🇦🇺 Australia
🇦🇹 Austria
🇧🇪 Belgium
🇧🇷 Brazil
🇨🇦 Canada
🇨🇳 China
🇨🇿 Czechia
🇩🇰 Denmark
🇫🇷 France
🇩🇪 Germany
🇬🇷 Greece
🇮🇱 Israel
🇮🇹 Italy
🇯🇵 Japan
🇳🇱 Netherlands
🇳🇴 Norway
🇵🇱 Poland
🇵🇹 Portugal
🇰🇷 South Korea
🇪🇸 Spain
🇸🇪 Sweden
🇨🇭 Switzerland
Turkey (Türkiye)
🇬🇧 United Kingdom
🇺🇸 United States
7 site(s) in Australia. Confirm current status and contact details directly with the trial site.
If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.